• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1263045 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
! i6 g& c1 Q3 b% ]$ ?) c" g7 H3 c2 TNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
: v6 m5 E) a: n+ Author Affiliations/ s5 E" k( g0 j* B3 e

4 @3 r2 a3 ]! D5 r6 C% s0 v1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan ) K7 ?% V' t9 b0 E  L
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
$ X/ N6 j* \% E3 v7 V3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ; F7 J/ @" Y9 c; h. |( u
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
" }- j, M% j, e! ?% g6 i5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan # @, {$ z5 V' V$ s: ~5 ~+ w) C
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
; c* u( c1 N6 l/ h9 h+ N! Z7Kinki University School of Medicine, Osaka 589-8511, Japan * i) k, x: x2 r: t+ e% r/ a, t
8Izumi Municipal Hospital, Osaka 594-0071, Japan , j" D2 G  g0 x! V
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
3 n; o5 X2 h. u" U& _- \' r0 ?Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp ) p3 i% z3 T& R& r& h! f
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
. j5 ^6 e  {2 J3 z  @* a9 e6 \2 i( t0 u* O7 Y/ x8 c% N
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type 6 D$ n# k- r% \, q& q! B5 C
, _8 D8 ?) ]+ w  s6 d/ Z! v! @
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato 5 c7 G/ E  _! ]- c; G6 e

* s3 H8 i+ y# o+ R5 pAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  + s4 t* M+ G: m/ Y
$ B$ q$ q3 e& V. U
Published online on: Thursday, December 1, 2011
' O! S- x$ q& o2 Q$ {
& F# o# R3 I' L/ E, {% ~Doi: 10.3892/ol.2011.507 1 p  M) }" j+ D) |4 n; _$ o

5 M7 z3 O5 z! Q, b- J- a% UPages: 405-410 5 _" T) d/ r/ a4 e
/ Y- @! [- ^) E4 \# ?
Abstract:1 \; i" n0 q* N. M
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.! T( ~  Q% K, e# G/ j
; ^$ p9 t7 F0 Z5 E
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population" ]3 J/ W7 x. ~0 G" K/ {
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
( q6 ]  y( T9 y! R: d' i+ Author Affiliations* K* ^8 H3 G9 \$ \- f4 k) c
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
% X0 u4 v; y: Z5 E$ V2Department of Thoracic Surgery, Kyoto University, Kyoto ' A! A' r# k9 }1 u* q  q- Z
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
3 W7 R4 n; Z3 L&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp % H( j- c+ u5 m4 S8 m# s
Received September 3, 2010. $ s" ]: U6 |; x. d1 V+ j5 u
Revision received November 11, 2010.
* e5 j( ^4 E9 U" a% ~9 U) aAccepted November 17, 2010. " Z, J- p! u, d" i6 i# n0 d0 X& c$ z
Abstract
: l" _, y* O4 l2 eBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. 3 B7 e+ a8 l* Y
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
4 g4 H1 J1 v% `* t8 [' g9 uResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. 4 l) g4 R. ~! B. G+ ^
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
# l7 @( E# q5 J$ p3 z- m
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。9 Y7 [' V; W$ Y6 K$ K/ U& S
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
& r5 s0 f# V/ O) e
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy" n4 s8 H! x! _1 N3 c1 `
http://clinicaltrials.gov/ct2/show/NCT01523587
4 x& w; @- z$ L" G0 I" v1 K/ C. H) O2 G' q9 a! Y; j
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
% M  [! i+ W" d# `' _http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 : Z. m' k* z/ W" ~" K9 }0 k# D; N
3 D% U" E( ?0 b" v% ]
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
3 Z: R. ^* o( @2 D至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦

& e4 I& ]. B7 T4 B3 p1 [2 ?没有副作用是第一追求,效果显著是第二追求。' T" k0 b$ {4 ?
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表